Immunotherapy of gynecological cancers.
Cervix cancer
Checkpoint inhibitors
Endometrial cancer
Immunotherapy
Ovarian cancer
Vaccine
Journal
Best practice & research. Clinical obstetrics & gynaecology
ISSN: 1532-1932
Titre abrégé: Best Pract Res Clin Obstet Gynaecol
Pays: Netherlands
ID NLM: 101121582
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
18
02
2019
accepted:
01
03
2019
pubmed:
21
4
2019
medline:
18
2
2020
entrez:
21
4
2019
Statut:
ppublish
Résumé
Oncology treatments have evolved from intuitive, via empiric, to the present precision medicine, with the integration of molecular targeted therapies in our treatment arsenal. The use of the patients' powerful immune system has long been contemplated and recently led to the integration of immunotherapy to overturn the well-documented inhibitory effects of the tumor on the immune system and restore it to a state of activity against the cancer. Recent favorable results have shown the value and effectiveness of immunotherapy against gynecological cancers. In particular, the checkpoint inhibitors, targeting the programmed death-1 (PD-1) pathway, have shown durable clinical responses with manageable toxicity. Several phase II and III clinical trials testing the association of different regimen of chemotherapy and immunotherapy are ongoing in gynecological cancers, and important results are expected. In this chapter, we outline the main principles of immunotherapy for gynecological cancers and summarize the current strategies used in clinical trials.
Identifiants
pubmed: 31003902
pii: S1521-6934(19)30032-X
doi: 10.1016/j.bpobgyn.2019.03.005
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
97-110Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.